Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexagon in Persistent Corneal Epithelial Defects
NCT01165450Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Nov 2011
- Primary completion
- Feb 2014
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
01
Overview
Phase 2, randomised, double-blind trial in persistent corneal epithelial defect (PED) comparing Nexagon with Vehicle only (2 arms). Primary endpoints: Percent Healing of the Corneal Epithelial Defect at 14 days and Incidence of Adverse Events at 28 days. Started Nov 2011; status: terminated.
02
Drugs
lufepirsen
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT01165450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01165450.